Adare Pharmaceuticals and NLS Pharmaceutics have formed a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and Attention Deficit Hyperactivity Disorder (ADHD). The collaboration will utilize Adare’s proprietary modified release technologies. The enhanced collaborative formulations are intended to deliver an effective pharmacokinetic profile, and are expected to improve patient compliance and disease management. MZD is a norepinephrine reuptake inhibi...